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Summary
  Purpose:  The aim of the study was to compare the influence of types of serum on the in vitro viability and 
on either spontaneous or rituximab (RIT)-induced apoptosis of chronic lymphocytic leukemia 
(CLL) cells.
  Methods:  The influence of fetal calf serum (FCS), patients’ autologous serum (AS) and human AB-serum 
(ABS), used alone and in combinations consisting of two of them (v/v-1:1), on RIT-dependent 
cytotoxicity, apoptosis, detection of active forms of caspases-3,-9,-8 and disruption of mitochon-
drial membrane potential (DYm) were assessed by flow cytometry. RIT was used at the concen-
tration of 10 µg/ml. The spontaneous apoptosis was assessed in culture without RIT.
  Results:  AS revealed the protective action on CLL cells, however this serum added in vitro to the cultu-
re either alone or in combination with FCS was the only one to allow RIT to exert its cytotoxic 
action against CLL cells. RIT-induced apoptosis involved changes in DYm and activation of ca-
spases-3,-8,-9 when AS+FCS was applicated. Drug induced apoptosis (DIA) was 6.02 and 0.34, 
when FCS+AS and FCS alone were used, respectively (p<0.01). The RIT-dependent cytotoxic 
effect decreased when FCS+AS or FCS+ABS were used, as compared to effect of AS used se-
parately. The cytotoxic effect of RIT did not depend on drug concentration, but on the type of se-
rum added to the culture.
  Conclusions:  The strongest cytotoxic effect of RIT in the presence of AS suggests that this drug activity to-
wards CLL cells is enhanced by known cytotoxic mechanisms, caspase-dependent apoptotic pa-
thway and possible influence of other extracellular factors present in the patients’ sera.
  Key words:	 chronic	lymphocytic	leukemia	•	Rituximab	•	Fetal	Calf	Serum	•	Autologous	Serum	•	AB-
Serum	•	apoptosis
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It has been well established that the accumulation of the 
chronic lymphocytic leukemia (CLL) cells in the bone mar-
row, peripheral blood, lymph nodes and eventually non-
-lymphoid organs results from both deregulated prolifera-
tion and the in vitro inhibition of apoptosis of leukemic 
cells. Currently, the association of purine analogues (flu-
darabine or cladribine) with an alkylating agent (cyclo-
phosphamide) and anti-CD20 monoclonal antibody (ritu-
ximab, RIT) is considered as the most powerful regimen 
in front-line therapy [10,12,13,16,17].
Although immunological phenomena involving comple-
ment-dependent cytotoxicity (CDC) and antibody-depen-
dent cellular cytotoxicity (ADCC) play the most important 
role in the mechanism of RIT action, this drug has also pro-
apoptotic properties [4,12]. RIT-dependent cytotoxicity in 
vitro requires the presence of appropriate serum in the cul-
ture medium. In numerous in vitro studies, the influence of 
RIT on the viability of CLL cells was tested in the presence 
of fetal calf serum (FCS) in the culture medium [2,5,18,19]. 
Some studies also checked the influence of some other sera 
on the RIT-dependent cytotoxicity such as autologous se-
rum (AS) or human AB-serum (ABS) [1,2,7,9,14,20]. So 
far, only few studies have aimed at comparing the in vitro 
effect of different types of sera on the survival of malignant 
cells or RIT-dependent cytotoxicity towards CLL cells [2,3]. 
Given this complexity of RIT action on CLL cells in vitro, 
the investigations on this action have to be carried out in the 
presence of a serum or sera combination which ensure the 
optimal conditions for both drug-induced cytotoxicity and 
apoptosis. It is then justified to undertake a study aiming 
at comparing the effect of different sera and their combi-
nations on the in vitro viability and apoptosis of CLL cells 
under the influence of RIT in order to optimize the experi-
mental conditions for further in vitro studies.
The aim of our study was then to evaluate the in vitro in-
fluence of three types of serum: FCS, AS and ABS, used 
either alone or in different combinations, on the viability 
of CLL cells incubated with RIT. We also compared the 
influence of FCS used alone or together with AS on the 
apoptosis of CLL cells incubated with RIT.
Streszczenie
  Cel pracy:  Celem pracy było porównanie wpływu różnych rodzajów surowic na żywotność oraz na sponta-
niczną lub indukowaną rytuksymabem (RIT) apoptozę komórek przewlekłej białaczki limfocy-
towej (PBL) in vitro.
  Metody:  Metodą cytometrii przepływowej oceniono wpływ płodowej surowicy cielęcej (FCS), surowicy 
autologicznej (AS) oraz ludzkiej surowicy AB (ABS) na cytotoksyczność i apoptozę, aktywność 
kaspaz 3, 9, 8 oraz zmianę potencjału mitochondrialnego (DYm) komórek PBL poddanych dzia-
łaniu RIT w stężeniu 10 µg/ml w hodowli in  vitro. Surowice stosowano pojedynczo lub w kom-
binacji dwóch z nich w stosunku 1:1. W hodowlach kontrolnych – bez RIT oceniano apoptozę 
spontaniczną.
  Wyniki:  Najwyższy odsetek komórek białaczkowych ulegających spontanicznej apoptozie stwierdzono 
po zastosowaniu wyłącznie FCS, podczas gdy najniższy odsetek tych komórek uzyskano stosu-
jąc tyko AS. Zastosowanie FCS+AS w hodowli komórek PBL poddanych działaniu RIT zwięk-
szało DYm, jak i ekspresję kaspaz 3, 8 i 9, w porównaniu z hodowlami kontrolnymi. Apoptoza 
indukowana lekiem wynosiła 6,02 i 0,34, odpowiednio w hodowlach z FCS+AS i z FCS użytym 
pojedynczo (p<0,01). Zastosowanie FCS+AS lub FCS+ABS zmniejszało natomiast efekt cyto-
toksyczny RIT, w porównaniu z uzyskanym po samodzielnym zastosowaniu AS. Cytotoksyczne 
działanie RIT nie zależało od stężenia leku, lecz od rodzaju surowicy dodanej do hodowli.
  Wnioski:  Najsilniejszy efekt cytotoksyczny RIT w obecności surowicy AS sugeruje, że jego aktywność 
wobec komórek PBL zwiększa się na skutek znanych mechanizmów cytotoksyczności, apopto-
zy zależnej od kaspaz oraz możliwego wpływu innych pozakomórkowych czynników obecnych 
w surowicy chorych.
  Słowa kluczowe:	 przewlekła	białaczka	limfocytowa	•	rytuksymab	•	płodowa	surowica	cielęca	•	surowica	
autologiczna	•	surowica	AB	•	apoptoza
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Patients
Peripheral blood samples were collected from 41 newly 
diagnosed CLL patients (19 females, 22 males) as a part 
of routine diagnostic procedures in the Department of 
Hematology, Medical University of Lodz. The mean age 
of patients was 62 years (range 21–83). The diagnosis was 
based on the IWCLL criteria [8]. The study was approved 
by the Local Ethics Committee. All specimens were col-
lected after written consent of patients.
Therapeutics
Rituximab (RIT; Mabthera, Roche, Switzerland) is com-
mercially available. The following final concentrations of 
the drugs were used: 5 µg/ml, 10 µg/ml and 20 µg/ml [5,7].
Isolation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from the heparinized blood by centrifugation in the 
Histopaque-1077 (Sigma-Aldrich, St. Louis, USA) and 
centrifuging on a density gradient by 3600 rpm for 20 mi-
nutes. The buffy coat of PBMNCs was isolated and wa-
shed twice in phosphate buffered saline (PBS) (Lonza, 
Belgium). Afterwards, PBMCs at a concentration of 1.0×106 
cells/ml were suspended in RPMI 1640 (PAA Laboratories 
GmbH, Austria) supplemented with antibiotics (strepto-
mycin 50 mg/ml, penicillin 50 IU/ml; Life Technologies, 
Scotland) [18]. Mean B-cell (CD19+) purity was >95% as 
measured by flow cytometry (FACS).
Cell culture conditions
To assess the influence of serum type on the viability and 
apoptosis of CLL cells, all cultures were incubated for 
24 and 48 hours, in RPMI 1640 medium containing 20% 
of appropriate type of serum, at 37°C, in the atmosphe-
re of 5% CO2 and full humidity. The following serum ty-
pes were used: 
1.   20% (v/v) heat inactivated fetal calf serum (HI-FCS) 
(Gibco, Life Technologies, Scotland).
2. 20% (v/v) autologous serum (AS).
3.   20% (v/v) human AB-serum (ABS)(PAA Laboratories 
GmbH, Austria).
4. 10% (v/v) HI-FCS + 10% (v/v) AS.
5. 10% (v/v) HI-FCS + 10% (v/v) ABS.
6. 10% (v/v) AS + 10% (v/v) ABS.
Assessment of the influence of serum type on the 
RIT-dependent cytotoxicity
The cytotoxic effect of RIT was tested using this drug in 
three concentrations listed above. The control cultures were 
incubated without RIT.
At the onset of cell cultures and after 24 and 48 hours, the 
absolute number of cells per culture was estimated using a 
hemocytometer. At the same time points the RIT-dependent 
cytotoxicity was assessed as a percentage of dead cells 
using propodium iodide (PI; Sigma Aldrich, Germany). 
Afterwards, PBMCs were washed twice with cold PBS and 
then resuspended in 100 µl of binding buffer containing 
10 µg/ml of PI and incubated for 15 minutes at room tempe-
rature in the dark. The fluorescence was measured immedia-
tely after staining by flow cytometer (FACSCalibur; Becton 
Dickinson, San Diego, USA) at 490”20 nm using FL1, and 
at 530”20 nm using FL3 standard fluorescent filter [6,18].
The drug-induced cytotoxicity (DIC) was calculated as the 
difference between the percentage of dead cells after incu-
bation with RIT and that in the control culture.
Assessment of the influence of serum type on the 
RIT-dependent apoptosis
The RIT-dependent apoptosis was tested after 24 or 48 ho-
urs of the culture containing either 20% (v/v) of FCS or 
the combination of 10% FCS + 10% AS and in the presen-
ce of RIT in the concentration of 10 µg/ml.
The percentage of apoptotic cells was measured by flow cy-
tometry using Annexin V (Ann-V; BD Pharmingen, USA). 
The cells were washed twice with cold PBS and then re-
suspended in 100 µl of binding buffer, containing 2 µl of 
FITC conjugated Ann-V. The fluorescence was measured 
as described above [6,18].
Apoptotic index (AI) was expressed as the percentage of 
Annexin V positive cells. Drug-induced apoptosis (DIA) 
was calculated as the difference between AI in the presen-
ce of RIT and the percentage of cells undergoing the spon-
taneous apoptosis in control cultures.
Detection of the active form of caspase-3, caspase-9 
and caspase-8 by flow cytometry
The apoptosis after the 48 hour culture supplemented 
with 10% FCS + 10% AS was quantitatively assessed 
by flow cytometry measuring the caspase-3 activity on 
FACSCalibour (Becton Dickinson, San Diego, USA), 
using Becton Dickinson Pharmingen PE Active Caspase-3 
Apoptosis Kit (San Diego, USA), according to the manu-
facturer’s protocol. Similarly, quantitive analyses of active 
forms of caspase-8 and caspase-9 were also performed on 
FACSCalibour using FAM-FLICA in vitro Caspase 8 Kit 
or FAM-FLICA in vitro Caspase 9 Kit (ImmunoChemistry 
Technologies, Bloomington, USA) respectively, according to 
the manufacturer’s protocol. Assays were done in duplicate.
Disruption of mitochondrial membrane potential 
(DYm)
Changes in mitochondrial transmembrane potential (DYm) 
were evaluated using MitoTracker Red CMX Ros kit 
(Invitrogen, Australia). After the 48 hour culture supple-
mented with 10% FCS + 10% AS, PBMNCs were centri-
fuged, and the supernatant above the cell pellet was rejec-
ted. Afterwards, the cell pellet was gently resuspended in 
the staining solution containing the MitoTracker probe, 
prepared according to the manufacturer’s protocol, and 
incubated for 30 minutes at 37°C. The cells were then re-
-pelleted by centrifugation and resuspended in fresh war-
med-up medium. Assays were done in duplicate and analy-
sed by flow cytometry (FACSCalibour, Becton Dickinson, 
San Diego, USA).
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Statistical differences between experimental and control 
cultures or between the effects of different concentrations 
of the drug tested were evaluated by Wilcoxon signed-rank 
test, and the p value less than 0.05 was considered as sta-
tistically significant.
results
Evaluation of the influence of serum type on the 
viability of CLL cells in vitro
The comparison of the influence of each of the sera tested 
on the viability of CLL cells in the absence of RIT reve-
aled the highest percentage of dead cells in the culture sup-
plemented with FCS, and the lowest in the presence of AS 
(p<0.03) (Table 1). The combinations of two types of se-
rum yielded the results which were comparable with each 
other and lower than FCS, but only the combinations of AS 
with either FCS or ABS gave the percentage of dead cells 
significantly lower than the results obtained with FCS alo-
ne (Table 1). For each serum used alone or in combination 
the percentage of dead cells was significantly higher in the 
48 hour culture than in corresponding the 24-hour one.
Evaluation of RIT influence on CLL cells viability 
depending on serum type
The comparison of the influence of different types of se-
rum used separately on the viability of CLL cells incuba-
ted with RIT at all three concentrations, showed the hi-
ghest cytotoxic effect, as compared to the control culture, 
when AS was added to the medium. A similar effect was 
observed after both 24 and 48 hours (p<0.03) (Table 2). 
The 48 hour incubation of PBMNCs with RIT at the con-
centration of 10 µg/ml and in the presence of AS, yielded 
the DIC value 18.6, whereas it was only 2.6 when FCS 
was used (Table 2).
The application of 1:1 (v/v) mixture of the two types of se-
rum revealed that the highest cytotoxic effect, as compared 
to the control culture, was demonstrated after 48 hours of 
incubation, and when FCS in combination with AS was 
added to the culture medium (p<0.0004) (Table 3). The in-
cubation of leukemic cells with RIT at the concentrations 
of 10 µg/ml or 20 µg/ml in the presence of FCS+AS re-
sulted in the similar DIC values for both RIT concentra-
tions (7.0 and 7.2; respectively). However, a longer incu-
bation period significantly increased the cytotoxic effect 
of the drug (p<0.002) (Table 3).
To evaluate the influence of serum type on the RIT-
dependent cytotoxicity, the effects of sera combinations 
with the effect of serum used separately were compared. 
In case of FCS used together with ABS, no significant dif-
ferences as compared to the results for each of serum used 
separately, were observed (Fig. 1A). The combinations of 
FCS either with AS or ABS decreased the cytotoxic effect 
of RIT as compared to the effect obtained with AS used 
separately (Fig. 1B, C).
Evaluation of RIT influence on percentage of 
apoptotic cells depending on serum type
The mean percentage of apoptotic CLL cells after 48   hours 
of incubation with FCS was significantly higher than that 
observed when FCS was used in combination with AS 
(17.28 and 11.09; respectively) (p=0.04) (Fig. 2). The in-
cubation of CLL cells with RIT at the concentration of 
10 µg/ml in the presence of FCS revealed differences in 
the percentage of apoptotic cells as compared to the con-
trol culture (17.6 and 11.09; respectively). Such difference 
was not observed when FCS alone was added to the culture. 
In case of FCS used in combination with AS, the DIA was 
6.02 and it was significantly higher than that obtained after 
incubation with FCS only (DIA=0.34) (p<0.01) (Fig. 2).
Evaluation of RIT influence on caspases expression 
and mitochondrial membrane potential depending on 
serum type
The mean expressions of caspases -9, -3 and -8 as well as 
changes in DYm were significantly higher when CLL cells 
Incubation period
Type of serum
(p<0.05)
FCS ABS AS FCS + ABS  FCS + AS ABS + AS
n=31 n=31 n=30 n=10 n=16 n=16
1 2 3 4 5 6
24 hours [A]
Mean 16.3 14.0 12.5 12.5 11.8 12.3 1 vs 2; 1 vs 3
1 vs 6; 2 vs 5
2 vs 6; 4 vs 5
SD 8.0 6.2 6.0 3.1 5.1 5.2
Range 6.2–32.5 5.6–30.5 1.7–28.6 8.9–18.2 5.7–22.4 5.0–22.9
48 hours [B]
Mean 27.1 21.3 18.7 19.5 18.5 17.2 1 vs 2; 1 vs 3
1 vs 5; 1 vs 6
2 vs 6; 3 vs 5
4 vs 6;
SD 13.9 9.3 10.9 8.0 9.6 7.8
Range 10.2–61.8 6.3–45.1 5.5–43.0 11.5–33.9 7.0–41.0 7.4–34.3
(p<0.005) A1 vs B1; A2 vs B2; A3 vs B3; A4 vs B4; A5 vs B5; A6 vs B6
Table 1.  The influence of serum type on CLL cells viability in vitro, after 24 and 48 hours incubation
FCS – fetal calf serum; ABS – serum devoid of anti-A and anti-B antibodies; AS – autologous serum; n – number of samples; Mean – mean percentage 
of dead cells (PI+); SD – standard deviation.
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period
Type of serum
(p<0.05)
FCS ABS AS
Control
Rituximab
Control
Rituximab
Control
Rituximab
5 
µg/ml
10 
µg/ml
20 
µg/ml
5 
µg/ml
10 
µg/ml
20 
µg/ml
5 
µg/ml
10 
µg/ml
20 
µg/ml
1 2 3 4 5 6 7 8 9 10 11 12
24 
hours 
[A]
n 31 31 31 31 31 31 31 31 30 30 30 30
1 vs 5; 1 vs 9
2 vs 10; 3 vs 11
4 vs 12; 6 vs 10
7 vs 11; 8 vs 12
Mean 16.3 16.2 16.8 16.5 14.0 18.2 18.0 18.2 12.5 26.5 27.9 30.0
SD 8.0 6.5 6.6 7.1 6.2 6.6 6.4 6.8 6.0 16.4 17.1 17.8
Range 6.2–32.5 5.6–33.1 6.6–30.9 5.6–33.6 5.6–30.5 8.5–38.8 6.4–30.9 4.7–34.0 1.7–28.6 5.0–81.2 4.9–83.2 4.8–83.9
DIC (%) 0.0 0.5 0.2 4.2 4.0 4.2 14.1 15.4 17.5
48 
hours 
[B]
n 31 31 31 31 31 31 30 31 30 30 30 29
1 vs 5; 1 vs 9
4 vs 8; 6 vs 10
7 vs 11; 8 vs 12
Mean 27.1 29.1 29.7 30.2 21.3 26.1 26.1 25.8 18.7 34.2 37.3 37.0
SD 13.9 14.3 14.3 14.9 9.3 10.3 9.4 8.9 10.9 18.2 18.9 21.2
Range 10.2–61.8 12.4–60.4 9.8–61.3 7.4–72.6 6.3–45.1 11.3–44.3 8.5–45.4 12.3–43.6 5.5–42.9 6.6–76.8 8.4–80.8 8.6–82.4
DIC (%) 2.0 2.6 3.1 4.8 4.8 4.5 15.5 18.6 18.3
(p<0.001) A1 vs B1; A2 vs B2; A3 vs B3; A4 vs B4; A5 vs B5; A6 vs B6; A7 vs B7; A8 vs B8; A9 vs B9; A10 vs B10;A11 vs B11; A12 vs B12
Table 2.  The influence of serum types on the viability of CLL cells incubated in vitro with rituximab in different concentrations
FCS – fetal calf serum; ABS – serum devoid of anti-A and anti-B antibodies; AS – autologous serum; n – number of samples; Mean – mean percentage 
of dead cells (PI+); SD – standard deviation; DIC – drug induced cytotoxicity
Incubation 
period
Type of serum
(p<0.05)
FCS + ABS FCS + AS ABS + AS
Control
Rituximab
Control
Rituximab
Control
Rituximab
5 
µg/ml
10 
µg/ml
20 
µg/ml
5 
µg/ml
10 
µg/ml
20 
µg/ml
5 
µg/ml
10 
µg/ml
20 
µg/ml
1 2 3 4 5 6 7 8 9 10 11 12
24 
hours 
[A]
n 10 10 10 10 16 16 16 16 16 16 16 16 1 vs 2; 1 vs 3
1 vs 4; 1 vs 5
2 vs 10; 5 vs 6
5 vs 7; 5 vs 8
6 vs 10; 7 vs 11
8 vs 12; 9 vs 10
9 vs 11; 9 vs 12
Mean 12.5 15.0 14.2 14.8 12.3 17.3 18.1 19.2 11.8 14.8 15.8 17.1
SD 3.1 2.0 3.0 3.0 5.2 8.0 8.3 7.7 5.1 6.2 7.1 7.8
Range 8.9–18.2 12.5–18.0 9.9–19.2 11.0–20.3 5.0–22.9 8.1–34.4 8.0–35.0 9.0–33.2 5.7–22.4 8.0–26.7 7.1–27.0 8.4–30.2
DIC (%) 2.5 1.7 2.3 5.0 5.8 6.9 3.0 4.0 5.3
48 
hours 
[B]
n 10 10 10 10 16 16 16 16 16 16 16 16 1 vs 2; 1 vs 3
1 vs 4; 1 vs 9
2 vs 10; 5 vs 6
5 vs 7; 5 vs 8
6 vs 10; 7 vs 11
9 vs 10; 9 vs 11
9 vs 12
Mean 19.5 22.1 23.2 24.6 18.5 23.1 25.5 25.7 17.2 20.4 21.8 24.0
SD 8.0 8.4 9.2 9.2 9.7 10.5 10.7 10.4 7.8 9.1 9.9 11.2
Range 11.5–33.9 12.3–36.3 12.1–39.0 12.8–39.8 7.0–41.0 9.3–41.8 11.1–43.9 11.2–45.8 7.4–34.3 10.0–40.4 9.8–44.8 11.6–48.0
DIC (%) 2.6 3.7 5.1 4.6 7.0 7.2 3.2 4.6 6.8
(p<0.01) A1 vs B1; A2 vs B2; A3 vs B3; A4 vs B4; A5 vs B5; A6 vs B6; A7 vs B7; A8 vs B8; A9 vs B9; A10 vs B10;A11 vs B11; A12 vs B12
Table 3.  The influence of serum combinations on the viability of CLL cells incubated in vitro with rituximab in different concentration
FCS – fetal calf serum; ABS – serum devoid of anti-A and anti-B antibodies; AS – autologous serum; n – number of samples; Mean – mean percentage 
of dead cells (PI+); SD – standard deviation; DIC – drug induced cytotoxicity
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       -               -               -               -               -       were incubated with 10 µg/ml RIT and in the presence of 
FCS+AS, as compared to the control cultures (23.1 and 
17.6; 22.1 and 17.3; 24.0 and 17.7; 34.5 and 28.5; respecti-
vely for caspase-9, caspase-3, caspase-8 and DYm) (Fig. 3).
dIscussIon
RIT, a monoclonal antibody against the surface antigen 
CD20 which is currently widely used in the management of 
B-cell lymphoid malignancies, has a complex mechanism of 
action involving both antibody- and complement-dependent 
Fig. 1.  The comparison of two different types of serum used separately or in combination on the viability of CLL cells incubated with different concentrations 
of rituximab, after 24 and 48 hours in vitro cultures. FCS – fetal calf serum; ABS – serum devoid of anti-A and anti B antibodies; AS – autologous 
serum; serum obtained from patient studied; plain columns – 24 hours incubation; columns with dots – 48 hours incubation; RIT – rituximab; 
* – difference statistically significant (p<0.01), # – difference statistically significant vs control (p<0.01)
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       -               -               -               -               -       cytotoxicity, and a direct induction of apoptosis. The im-
portance of soluble extracellular factors for RIT action in 
vivo renders it necessary to devise appropriate cellular cul-
ture conditions for in vitro studies of the mechanism of its 
action. The type of serum added to the culture medium is 
crucial for providing the experimental system with all fac-
tors necessary for the drug to be able to exert its action to-
wards target cells.
In the first part of our study we checked the influence of sera 
added to short-term culture on the viability of CLL cells. 
The cultures were supplemented with FCS, ABS or AS se-
parately or with their 1:1 mixtures: FCS+ABS, FCS+AS 
or ABS+AS. We observed the highest percentage of dead 
cells when FCS was added to the culture separately. The 
viability of CLL cells was the highest when AS alone or 
the combinations of the FCS+AS or ABS+AS were used. 
Those observations favor the hypothesis that autologous 
serum used either separately or in combination with FCS 
or ABS exerts a protective action on CLL cells in vitro, 
probably due to antiapoptotic cytokines present in patients’ 
sera in vivo. This finding may account, at least partially, 
for the generally known phenomenon that the CLL cells 
quickly undergo apoptosis when cultured in vitro, but the-
ir lifespan in vivo is very long. It is also possible, that the 
high rate of cell death in FCS-supplemented culture is at-
tributable, at least partially, to a low concentration of albu-
mins in such culture medium. Pettitt et al. [15] noted that 
the medium supplemented with FCS, in which CLL cells 
are usually cultured, contained a concentration of albumin 
twofold lower than required for its maximal antiapoptotic 
effect. These authors underlined that the concentration of 
albumin in the culture medium is important for the survi-
val of CLL cells, since the viability of these cells was fo-
und to be consistently higher after a 4 day culture supple-
mented with 10 mg/ml of bovine serum albumin (BSA) 
than in the culture with 10% FCS.
As the type of serum itself modifies the CLL lymphocytes 
viability in the culture in vitro, this property of the culture me-
dium must be taken into consideration when the cytotoxicity 
of RIT is tested in such culture. Previous publications on this 
issue were based on different experimental conditions; in a 
study of Smolewski et al. [18] 20% (v/v) of HI-FCS was used, 
Zent et al. [20] added to the culture human serum complement, 
Alonso et al. [1] incubated cells with RIT in the presence of 
10% of human AB serum. In other studies, Moran et al. [11] 
used BSA in the concentration of 10 mg/ml, Bellosillo et al. 
[2] used either FCS or ABS, Patz et al. [14], Furlan et al. [7] 
and Johnson et al. [9] used autologous serum, and Bomstein 
et al. [3] compared the effect of FCS and AS.
To the best of our knowledge, the present study is the first 
one to compare the cytotoxic effect of RIT in vitro in the 
presence of such spectrum of sera and their combinations, 
on CLL cells viability and apoptosis.
We evaluated the DIC after 24 and 48 hours of incubation 
and, as expected, we found that a longer incubation period 
significantly increased cytotoxic effect of RIT. The appe-
arance of this action of RIT was strongly dependent on the 
serum added to the culture medium. RIT led to a signifi-
cant increase of cell death as compared to control culture 
only in the presence of AS. When ABS was used for the 
culture, RIT brought about some increase of cell death rate 
as compared to the controls, but this increase did not re-
ach the threshold of statistical significance. We could not 
observe any cytotoxic effect of RIT in the cultures supple-
mented with heat-inactivated FCS. Moreover, the rate of 
dead cells was similar for all RIT concentrations used. It is 
then plausible, that the autologous serum, i.e. the natural 
medium for circulating CLL lymphocytes in in vivo con-
ditions, prevents leukemic lymphocytes from spontaneous 
death in vitro, but enhances the cytotoxic effect of RIT on 
those cells. Moreover it is noteworthy, that the cytotoxic ef-
fect of RIT was significantly higher in the presence of AS 
as compared to ABS. It therefore seems legitimate to hy-
pothesize that the drug in question fails to exert its action 
in the presence of HI-FCS not only due to the lack of pro-
teins of complement system in this medium, but also be-
cause of the absence of some other factors which are pre-
sent in the patient’s serum but not in healthy AB donors. 
In other terms, RIT action towards CLL cells probably re-
quires the presence of some exogenous substances conta-
ined solely in the patient’s serum.
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       -               -               -               -               -       Our results are somewhat discordant with observations pu-
blished by Bellosillo et al. [2] who evaluated in vitro the cy-
totoxic effect of RIT on CLL cells in the presence of ABS. 
They demonstrated that no effect was observed when cells 
were incubated with RIT in the presence of 10% heat-inac-
tivated FCS, however the addition of human AB serum as 
a source of complement produced a cytotoxic effect after 
24 hours of incubation. Additionally, this effect was do-
se-dependent for both RIT and ABS and could be detec-
ted using doses as low as 10 µg/ml and 1% ABS. However, 
the most significant cytotoxic effect was observed when 50 
µg/ml and 10% ABS were used. Our failure to confirm the 
dose-dependency of RIT action on CLL cells might result 
from lower drug concentration than that used by Bellosillo 
et al. [2], as well as a smaller size of our sample.
Our above-quoted findings suggest that the autologous se-
rum provides the best experimental conditions for in vitro 
assays of RIT toxicity. However, when planning a set of 
experiments one might face an ethical difficulty to obtain 
a quantity of patients’ sera which would be sufficient for 
performing the experiments in the best conditions. We then 
wished to test the different combinations of two out of three 
sera in order to find out which one would be suitable for this 
purpose and might be used instead of AS as a single agent.
The combination of FCS+AS allowed higher DIC than 
FCS used alone or together with ABS. Therefore we cho-
se to carry on further experiments on the mechanism of 
RIT-dependent apoptosis in the culture supplemented with 
FCS mixed with AS. We checked the total percentage of 
apoptotic cells and then the different stages of apoptotic 
cascade (changes in mitochondrial transmembrane poten-
tial and the expression of active forms of caspases-9, -3 
and -8) were assessed.
Firstly, we compared the occurrence of spontaneous apop-
tosis of CLL cells after the 48-hour culture in the presen-
ce of FCS alone and FCS combined with AS. The mean 
percentage of cells undergoing apoptosis, i.e. displaying 
the affinity to Annexin V, was 17.28 and 11.09 respecti-
vely. This difference was statistically significant (p=0.04) 
which means that the presence of AS in the culture medium 
decreases not only the overall percentage of cell death, but 
also the occurrence of apoptosis.
Therefore, we checked the influence of RIT on apoptosis 
of CLL cells cultured in the presence of FCS combined 
with AS and found that both the expression of all caspa-
ses and the changes in DYm were significantly higher when 
the cells were incubated with RIT than in control cultu-
res. This suggests that both extrinsic and intrinsic apopto-
tic pathway are involved in RIT-dependent apoptosis. RIT 
added to the cultures supplemented with FCS in associa-
tion with AS allowed to obtain on average 17% of apoptotic 
cells, which is significantly higher than the control culture 
(11%; DIA=6.02). Our results are not very different from 
those obtained by Patz et al. [14] who used AS separately 
at the concentration of 20%, and incubated the CLL cells 
in the presence of 10 mg/ml of RIT. Those authors obta-
ined 13% and 20% of apoptotic cells, respectively for the 
whole peripheral blood and freshly isolated CLL cells. It 
corroborates our observation that the use of AS in associa-
tion with FCS provides appropriate conditions for in vitro 
studies on RIT-induced CLL cells apoptosis.
conclusIons
In conclusion, we found that in short-term CLL culture, 
the viability of cells was the lowest when FCS was used 
alone, whereas the highest in vitro viability of these cells 
was stated in the presence of AS. In contrast to the spon-
taneous cell death decreased by the use of AS, we found 
that this serum used alone or in combination with FCS was 
the only one to significantly enhance the cytotoxic effect 
of RIT on CLL cells in vitro. Additionally we stated, that 
the RIT action on CLL cells triggers an apoptosis cascade 
including the activation of some caspases and changes in 
mitochondrial transmembrane potential. Finally, we sug-
gest that the antitumor activity of RIT against CLL cells is 
mediated by complex cytotoxic mechanisms, caspase-de-
pendent apoptotic pathway and a possible action of some 
other extracellular factors present in the patients’ sera. 
Therefore, the use of appropriate serum as a supplemen-
tation of culture medium is essential for achieving the an-
titumor effect of RIT in vitro.
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